PMID- 31099662
OWN - NLM
STAT- MEDLINE
DCOM- 20191113
LR  - 20191113
IS  - 1548-8756 (Electronic)
IS  - 1548-8748 (Linking)
VI  - 39
DP  - 2019 Jan
TI  - Redrawing the Lines: The Next Generation of Treatment in Metastatic Breast 
      Cancer.
PG  - e8-e21
LID - 10.1200/EDBK_237419 [doi]
AB  - Although not considered curative in nature, new therapeutic advances in 
      metastatic breast cancer (MBC) have substantially improved patient outcomes. This 
      article discusses the state-of-the-art and emerging therapeutic options for 
      management of MBC. BC systemic therapy targets multiple key pathways, including 
      estrogen receptor signaling, HER2 signaling, and phosphoinositide 3-kinase 
      (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling. 
      Other therapeutic strategies include targeting DNA repair, inhibiting immune 
      checkpoints, and developing antibody-drug conjugates. Although surgery 
      historically was reserved for palliation of symptomatic, large, or ulcerating 
      masses, some data suggest a possibly expanding role for more aggressive 
      locoregional therapy in combination with systemic therapy. As technology 
      develops, biomarker-specific, line-agnostic, and receptor-agnostic treatment 
      strategies will redraw the current lines of MBC care. However, tumor 
      heterogeneity remains a challenge. To effectively reshape our approach to MBC, 
      careful consideration of the patient perspective, the costs and value of novel 
      treatments, and accessibility (especially in developing countries) is paramount.
FAU - Savard, Marie-France
AU  - Savard MF
AD  - 1 Tom Baker Cancer Centre, Department of Oncology, Cumming School of Medicine, 
      University of Calgary, Calgary, Alberta, Canada.
FAU - Khan, Omar
AU  - Khan O
AD  - 1 Tom Baker Cancer Centre, Department of Oncology, Cumming School of Medicine, 
      University of Calgary, Calgary, Alberta, Canada.
FAU - Hunt, Kelly K
AU  - Hunt KK
AD  - 2 Department of Breast Surgical Oncology, Division of Surgery, University of 
      Texas MD Anderson Cancer Centre, Houston, TX.
FAU - Verma, Sunil
AU  - Verma S
AD  - 1 Tom Baker Cancer Centre, Department of Oncology, Cumming School of Medicine, 
      University of Calgary, Calgary, Alberta, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190517
PL  - United States
TA  - Am Soc Clin Oncol Educ Book
JT  - American Society of Clinical Oncology educational book. American Society of 
      Clinical Oncology. Annual Meeting
JID - 101233985
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biomarkers, Tumor
MH  - Breast Neoplasms/etiology/metabolism/*pathology/*therapy
MH  - Clinical Decision-Making
MH  - Combined Modality Therapy/methods
MH  - Disease Management
MH  - Female
MH  - Humans
MH  - Molecular Targeted Therapy
MH  - Mutation
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Recombinational DNA Repair
MH  - Signal Transduction/drug effects
EDAT- 2019/05/18 06:00
MHDA- 2019/11/14 06:00
CRDT- 2019/05/18 06:00
PHST- 2019/05/18 06:00 [entrez]
PHST- 2019/05/18 06:00 [pubmed]
PHST- 2019/11/14 06:00 [medline]
AID - 10.1200/EDBK_237419 [doi]
PST - ppublish
SO  - Am Soc Clin Oncol Educ Book. 2019 Jan;39:e8-e21. doi: 10.1200/EDBK_237419. Epub 
      2019 May 17.